CCGs poised to defy pharma by switching to cheaper, unlicensed drug


Clinical commissioning groups across England are mulling the use of an unlicensed drug which could save the NHS millions of pounds, HSJ has learned

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here